Two rapid urine screening tests, the Chemstrip LN (BioDynamics, Indianapolis, Ind.) and the Bac-T-Screen urine screening device (Marion Laboratories, Inc., Kansas City, Mo.), were evaluated as techniques to predict bacteriuria as quantitated by either conventional culture or the AutoMicrobic system (Vitek Systems, Inc., Hazelwood, Mo.). A total of 666 urine specimens were analyzed by both screening tests as well as the AutoMicrobic system and quantitative culture. The sensitivities of both Chemstrip LN and Bac-T-Screen for the detection of low levels of bacteriuria (210 CFU/ml) were comparable (73.3 and 74.4%, respectively) and were too low to recommend their use as a primary urine screen. Their excellent predictive value of a negative result at the 105 CFU/ml level (96 and 97.5%, respectively) makes them potentially useful in predicting urine specimens with <105 CFU/ml. The use of either of these tests in combination with the AutoMicrobic system markedly decreased the time required to classify urine specimens. Their low cost relative to the AutoMicrobic system urine card makes the use of either test cost effective as a screen for the AutoMicrobic system.
A great deal of effort has been spent in the last several years in attempts to develop rapid, efficient methods of screening the large numbers of urine specimens submitted to the clinical microbiology laboratory. These screening tests include microscopic (9, 17) , chemical (2, 4, 17, 22) , and automated methods (2, 6, 8, [10] [11] [12] [13] [14] [15] 18) . The purpose of rapid screening of urine specimens is threefold. First, rapid screening may provide information to the clinician in a more timely manner, resulting in appropriate antibiotic therapy or other therapeutic actions. Second, a truly rapid screening technique may encourage clinicians to screen more of the population, including asymptomatic persons (3) . This may result in improved care of patients, such as the elderly, who may be at risk for asymptomatic bacteriuria (3, 7, 23) . Third, rapid screening methods may assist the laboratory in developing a more efficient, cost-effective approach to the processing of urine specimens. This may include the elimination of those specimens that are negative by the screening test or processing them by an alternative, cost-effective manner.
With the recent proliferation of rapid urine screening tests there are several that may be useful in the clinical microbiology laboratory. Two of the most promising are the Bac-TScreen (BTS; Marion Laboratories, Inc., Kansas City, Mo.), a filtration-staining device for bacterial detection (6, 14, 15) , and the Chemstrip LN (BioDynamics, Indianapolis, Ind.) for the detection of leukocytes and nitrite in urine (2, 4, 22) . Both of these tests have been shown to reliably detect significant bacteriuria and to have an excellent predictive value of a negative result (PVN) in studies versus quantitative culture (2, 4, 6, 14, 15, 22) . Because they are both independent of bacterial growth they are very rapid, providing results in 2 to 3 min.
There are many studies describing the use of these two tests as primary urine screens (4, 6, 14, 15, 22) ; however, several issues remain which should be investigated further concerning their role in the clinical laboratory. One of the more important issues is the ability of these (and other) screening tests to detect low-level bacteriuria (102 to <105 CFU/ml). Although several studies have documented the ability of both the Chemstrip LN and the BTS to detect bacteriuria at 2105 CFU/ml (4, 6, 14, 15, 22) , relatively few have compared their ability to detect lower levels of bacteruria (2, 6, 14) . Another interesting issue is the utility of performing these rapid urine screens in tandem with a highly automated urine processing instrument such as the AutoMicrobic system (AMS; Vitek Systems, Inc., Hazelwood, Mo.). Despite the fact that previous investigators have suggested that the performance of a screening test before processing urine specimens on the AMS would result in a much more cost-effective approach to automated urine culture and identification (8, 21) , there are very few published studies evaluating the role of the newer urine screening tests, such as the Chemstrip LN and the BTS, in conjunction with the AMS (2).
Because we utilize both quantitative culture and the AMS for processing urine specimens in our laboratory, we were interested in investigating the two issues described above. Thus, we compared the relative abilities of the Chemstrip LN and the BTS to detect bacteriuria at levels of 2103, 2104, and 2105 CFU/ml as determined by quantitative culture; in addition, we evaluated the role of each test in predicting bacteriuria at the breakpoint of i105 CFU/ml determined by the AMS. We also examined the effect of performing each of these screening tests in tandem with the AMS on the time and cost of processing urine specimens in our laboratory.
( Urine screening with the BTS. All specimens were screened by the BTS as described previously (6, 14, 15) and in accordance with the manufacturer's instructions. The filters were read immediately after staining. A staining intensity of 1+ or greater was considered positive. Specimens that clogged the filter or produced staining due to urinary pigments were excluded from analysis.
Time and cost analysis. At the conclusion of this study the data were evaluated to determine the potential effect of the rapid screening tests on the time and cost of processing urine specimens on the AMS. To accomplish this we examined the experimental data according to three different urine-processing protocols. The first protocol was simply the processing of all urine specimens by the AMS alone. The second and third protocols required that all urine specimens first be screened by either the Chemstrip LN (LN-AMS protocol) or the BTS (BTS-AMS protocol) and that only those with a positive screening test be processed on the AMS. Specimens with negative screening tests were considered presumptively negative (<105 CFU/ml) for significant bacteriuria. Using the data available on the AMS printout, we calculated the average time required to classify the urine specimens as containing -105 or <105 CFU/ml for each protocol. In the LN-AMS and BTS-AMS protocols a value of 2 min was assigned to each specimen with a negative screening test.
The cost of materials required for each urine processing protocol was determined by using the actual cost of reagent purchase for our laboratory. The cost of instruments was not included in this analysis.
Statistical calculations. Statistical analysis was performed by chi-square testing with Yates' correction (5). The sensitivity, specificity, and predictive values were calculated for the screening tests as previously described (15) .
RESULTS
Of the 666 specimens processed during the study, 90 (13.5%) could not be analyzed due to interfering pigments in 70 specimens (57 BTS only, 11 BTS and Chemstrip LN, 2 Chemstrip LN only) and clogging of the filter in 20 specimens (all BTS). This is similar to the rate of pigmentation and clogging reported in previous studies with the BTS (6, 14, 15) . The remaining 576 specimens were processed by the Chemstrip LN, BTS, quantitative culture, and the AMS as described above.
Comparison Table  6 . With the protocols described above, the average time to detection, quantitation, and identification for all 576 urine specimens was 11.1 h for the AMS alone, 4.5 h for the LN-AMS protocol, and 4.2 h for the BTS-AMS protocol.
Because the major expense in processing urine specimens on the AMS is the cost of materials (urine cards specifically), we estimated the impact of using these screening tests in conjunction with the AMS on the cost of supplies necessary to process the 576 urine specimens in this study. We calculated the savings in supplies that would be achieved if all urine specimens were processed according to either the LN-AMS or BTS-AMS protocols. Specimens in either protocol with a negative screening test would be processed by routine culture. If all 576 specimens included in this study were processed by the AMS the total cost for supplies (including a single back-up plate for susceptibility testing) would be $1,560.96, whereas if the specimens were processed by the LN-AMS protocol only 257 (45%) would be run on the AMS and the total cost for processing all 576 would be $878.57, a savings of $682.39 ($1.18 per specimen) ( Table   7 ). Although the BTS-AMS protocol would result in even fewer specimens processed on the AMS, the overall savings in materials would be considerably less than that seen with the LN-AMS protocol ($332.04 versus $682.39) because of the greater cost of the BTS ($0.98 per test) versus the Chemstrip LN ($0.15 per test).
DISCUSSION
The number of CFU of bacteria per milliliter of urine that is considered clinically significant is controversial (1, 16, 19, 20) . Currently accepted breakpoints for significant bacteriuria range from .102 to 2105 CFU/ml depending upon the patient population studied (1, 16, 19, 20) . Because colony counts of <105 CFU/ml may be significant in catheterized patients (16) and symptomatic women (19, 20) , it is important to assess the ability of the newer urine screening tests, such as the Chemstrip LN and BTS, to detect levels of bacteriuria of <105 CFU/ml as well as >105 CFU/ml. The purpose of the present investigation was not to evaluate which breakpoint was most predictive of infection in the population studied, but rather to compare the abilities of two urine screening tests to predict the results of two accepted methods of quantitating bacteriuria, conventional culture and the AMS.
The results of this study are consistent with previous work performed in our laboratories (15) and in others (2, 4, 6, 14, 22) comparing the Chemstrip LN and the BTS with quantitative culture. Both tests were rapid and simple to perform and interpret. The sensitivities of both the Chemstrip LN and the BTS fot the detection of significant bacteriuria at breakpoints of -103, .104, and i105 CFU/ml were compa- Likewise, certain urine processing decisions within the laboratory may be facilitated by using these screening tests (1, 2, 6, 15) . Because these tests are so rapid and simple to perform they can potentially be used to great advantage in conjunction with an automated urine processing system such as the AMS.
The AMS has been shown to be an accurate, relatively rapid, cost-effective system for specimens with -105 CFU/ml and provides detection, quantitation, and identification in 4 to 9 h in a high percentage of these specimens (8, 10, 11, 21) . However, it is not cost effective for processing specimens with <105 CFU/ml (8, 21 (Table 5 ). In addition, we have shown that the use of either the Chemstrip LN or the BTS as a screening test could reduce the total number of specimens to be processed by the AMS by 55% (Chemstrip LN) to 65% (BTS). These findings are quite similar to the 65% decrease reported by Bartlett et al. with Chemstrip LN as a screen (2) . As suggested above, those specimens with negative screening tests could then be reported as presumptively negative (or containing < 105 CFU/ml) or processed by an alternative low-cost method (conventional culture) to ensure that nothing is missed (16, 19 ). By enriching the population of urine specimens processed on the AMS with those containing 2.10 CFU/ml, we were able to decrease the time and cost of processing urine specimens in our laboratory (Tables 6 and 7 (2) .
In conclusion, we have shown that the Chemstrip LN and BTS have comparable sensitivities and predictive values at low levels of bacteriuria (2 103 CFU/ml) as well as at the traditional breakpoint of -105 CFU/ml. Although we feel that the rather low sensitivity of both tests somewhat limits their usefulness in the clinical laboratory, we have demonstrated their potential application in combination with the AMS. The low cost of the Chemstrip LN ($0.15 per test) and its simplicity make it most attractive for use in our urineprocessing system. However, we feel that either screening procedure could be utilized in decreasing the overall time and cost of processing urine specimens on the AMS.
